natgillin/translations-raw huggingface dataset:
In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, HDL and LDL. 
Združena analiza vrednosti lipidov v s placebom nadzorovanih kliničnih preskušanjih pri odraslih ni pokazala, da bi aripiprazol klinično pomembno spremenil vrednosti skupnega holesterola, trigliceridov, lipoproteinov velike gostote (HDL) in lipoproteinov majhne gostote (LDL).
In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development. 
Pri študijah s ponavljajočimi se odmerki pri mladih podganah in psih je bil profil toksičnosti aripiprazola primerljiv s profilom toksičnosti pri odraslih živalih.
Aripiprazole Mylan Pharma is for oral use. 
Zdravilo Aripiprazol Mylan Pharma je namenjeno za peroralno uporabo.
Cardiovascular disorders 
Srčnožilne bolezni
Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group. 
teden vidno izboljšanje za 14,97 točk po lestvici TTS-YGTSS od izhodiščne vrednosti, v primerjavi z izboljšanjem za 9,62 točke pri skupini, ki je prejemala placebo.
In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. 
V kliničnih preskušanjih, ki so trajala eno leto ali manj, so med zdravljenjem z aripiprazolom občasno poročali o diskineziji, nastali med zdravljenjem.
Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8). 
Tudi pri aripiprazolu se lahko pojavijo preobčutljivostne reakcije v obliki simptomov alergije (glejte poglavje 4.8).
In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo. 
Pri bolnikih s shizofrenijo je bila pojavnost akatizije pri uporabi aripiprazola 6,2 %, pri uporabi placeba pa 3,0 %.
In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy. 
V 6-tedenskem s placebom nadzorovanem preskušanju pri bolnikih z manično ali mešano epizodo bipolarne motnje I s psihotičnimi simptomi ali brez njih, ki so bili po 2 tednih pri terapevtskih koncentracijah v serumu deloma neodzivni na samostojno zdravljenje z litijem ali valproatom, se je po uvedbi aripiprazola kot dodatnega zdravila povečala učinkovitost pri zmanjšanju maničnih simptomov v primerjavi s samostojnim zdravljenjem z litijem ali valproatom.
• uncontrollable twitching, jerking or writhing movements, restless legs, 
• nenadzorovano trzanje ali sunkoviti gibi, nemirne noge,
Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. 
Pri bolnikih s shizofrenijo in bipolarno manijo je povečanje telesne mase pogosto, in sicer zaradi komorbidnih stanj, uporabe antipsihotikov, za katere je znano, da povzročajo povečanje mase, in zaradi neurejenega življenjskega sloga.
Aripiprazole did not impair fertility in reproductive toxicity studies. 
V raziskavah reprodukcijskih toksičnih učinkov aripiprazol ni prizadel plodnosti.
Aripiprazole Mylan Pharma tablets contain maltose. 
Tablete zdravila Aripiprazol Mylan Pharma vsebujejo maltozo.
Blood glucose increased Glycosylated haemoglobin increased Blood glucose fluctuation Increased creatine phosphokinase 
Preiskave zvišana vrednost glukoze v krvi zvišana vrednost glikoziliranega hemoglobina nihanje vrednosti glukoze v krvi zvišana aktivnost keratinfosfokinaze
Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. 
Pri mlajših bolnikih je tveganje za pojav neželenih učinkov aripiprazola večje.
• not enough sodium in the blood, 
• nezadostna koncentracija natrija v krvi,
Before treatment with Aripiprazole Mylan Pharma tell your doctor if you suffer from 
Pred začetkom zdravljenja z zdravilom Aripiprazol Mylan Pharma morate obvestiti zdravnika, če:
What Aripiprazole Mylan Pharma is and what it is used for 
Kaj je zdravilo Aripiprazol Mylan Pharma in za kaj ga uporabljamo
The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6. 
Pri osebah, ki dobro presnavljajo s CYP2D6 je srednji razpolovni čas izločanja aripiprazola približno 75 ur, pri osebah, ki slabo presnavljajo pa približno 146 ur.
Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. 
Patološko hazardiranje in druge motnje nadzora impulzov Pri bolnikih se lahko poveča impulzivnost, zlasti želja po igrah na srečo, med jemanjem aripiprazola pa teh niso več sposobni nadzorovati.
The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. 
Pojavnost hipoprolaktinemije ali znižane ravni prolaktina v serumu pri bolnikih, zdravljenih z aripiprazolom, je bila 0,4 % v primerjavi s skupino s placebom (0,02 %).
Warnings and precautions Talk to your doctor before taking Aripiprazole Mylan Pharma 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Aripiprazol Mylan Pharma se posvetujte z zdravnikom.
In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. 
V kliničnih preskušanjih so med zdravljenjem z aripiprazolom poročali o redkih primerih MNS-a.
The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. 
AUC aktivnega presnovka dehidroaripiprazola se je zmanjšala za 32 %, njegova Cmax pa za 47 %.
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for aripiprazole is 10 mg/day administered on a once-a-day schedule without regard to meals. 
Manične epizode pri bipolarni motnji I pri mladostnikih, starih 13 let in več: priporočeni odmerek aripiprazola je 10 mg enkrat na dan ne glede na obrok hrane.
In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. 
V s placebom nadzorovanih preskušanjih je bila pojavnost akatizije pri bolnikih z bipolarno motnjo pri uporabi aripiprazola 12,1 %, pri uporabi placeba pa 3,2 %.
Kaplan-Meier relapse rates at week 16 were 35% for aripiprazole and 52% for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). 
Razmerje ogroženosti za ponovitev v 16 tednih (aripiprazol/placebo) je bilo 0,57 (statistično nepomembna razlika).
Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8). 
Znaki in simptomi serotoninskega sindroma se lahko pojavijo še posebej pri sočasni uporabi z drugimi serotoninergičnimi zdravili, kot so selektivni zaviralci privzema serotonina/selektivni zaviralci privzema serotonina in noradrenalina ali z zdravili, ki zvišujejo koncentracijo aripiprazola (glejte poglavje 4.8).
Manic episodes in Bipolar I Disorder in children and adolescents Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline. 
Manične epizode pri bipolarni motnji I pri otrocih in mladostnikih Uporabo aripiprazola so raziskovali v 30-tedenskem s placebom nadzorovanem preskušanju, ki je vključevalo 296 otrok in mladostnikov (10-17 let), ki so ustrezali kriterijem DSM-IV za bipolarno motnjo I z maničnimi ali mešanimi epizodami s psihotičnimi lastnostmi ali brez njih, in so imeli v izhodišču oceno ≥ 20 po lestvici Y-MRS. Izmed bolnikov, ki so bili vključeni v primarno analizo učinkovitosti, je imelo 139 bolnikov sočasno tudi diagnozo motnje pomanjkanja pozornosti (ADHD‘Attention deficit hyperactivity disorder').
In another 12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. 
V drugem 12-tedenskem preskušanju je bila pojavnost EPS pri bolnikih, ki so se zdravili z aripiprazolom 26,6 %, pri bolnikih, ki so se zdravili z litijem pa 17,6 %.
A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity. 
Raziskava z enim samim odmerkom pri preiskovancih z različno stopnjo jetrne ciroze (razredi A, B in C po Child-Pughu) ni pokazala pomembnega učinka okvare jeter na farmakokinetiko aripiprazola in dehidroaripiprazola.
Following a single oral dose of [14C]-labelled aripiprazole, approximately 27% of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. 
Po enem samem peroralnem odmerku aripiprazola, označenega s [14C], se je približno 27 %
Talk to your doctor about the best way to feed your baby if you are taking this medicine. 
Če prejemate to zdravilo, se z zdravnikom posvetujte o najprimernejših načinih hranjenja otroka.
Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole. 
Populacijska farmakokinetična analiza ni pokazala klinično pomembnih učinkov rase na farmakokinetiko aripiprazola.
• nervousness, 
• živčnost,
Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. 
Pri uporabi antipsihotikov so poročali o primerih venske trombembolije (VTE).
However, the estimation of the HR for the younger (13-14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect. 
Vendar pa izračun razmerja tveganja za mlajšo skupino (13 do 14 let) ni bil natančen zaradi manjšega števila bolnikov v tej skupini (aripiprazol, n = 29; placebo, n = 12).
Schizophrenia in adolescents aged 15 years and older In a short-term placebo-controlled clinical trial involving 302 adolescents (13-17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo): Somnolence/sedation and extrapyramidal disorder were reported very commonly (≥ 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (≥ 1/100, < 1/10). 
V kratkotrajnem, s placebom nadzorovanem kliničnem preskušanju, ki je vključevalo 302 mladostnika (13-17 let) s shizofrenijo, so bili neželeni učinki po pogostnosti in vrsti podobni kot pri odraslih, z izjemo naslednjih neželenih učinkov, ki so bili pri mladostnikih, ki so prejemali aripiprazol, pogostejši kot pri odraslih, ki so prejemali aripiprazol (in pogostejši kot pri placebu): somnolenca/sedacija in ekstrapiramidne motnje so bili zelo pogosti ( ≥ 1/10), suha usta, povečan apetit in ortostatska hipotenzija pa pogosti ( ≥ 1/100, < 1/10) neželeni učinki.
Excipient with known effect 168 mg of maltose per tablet 
168 mg maltoze na tableto.
Schizophrenia in adolescents aged 15 years and older: the recommended dose for aripiprazole is 10 mg/day administered on a once-a-day schedule without regard to meals. 
Shizofrenija pri mladostnikih, starih 15 let in več: priporočeni odmerek aripiprazola je 10 mg enkrat na dan ne glede na obroke hrane.
• agitation, 
• vznemirjenost,
Suicidality 
Samomorilne misli
However, your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day. 
Priporočeni odmerek za odrasle je 15 mg enkrat na dan, toda vaš zdravnik vam lahko predpiše odmerek, ki je manjši ali večji, do največ 30 mg enkrat na dan.
Weight gain should be monitored in adolescent patients with bipolar mania. 
Pri mladostnikih z bipolarno manijo je treba meriti povečanje telesne mase.
The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. 
V stabilizacijski fazi (do 26. tedna) se je telesna masa bolnikov, ki so prejemali aripiprazol, v povprečju povečala za 3,2 kg, v drugi (16-tedenski) fazi preskušanja pa se je telesna masa bolnikov, ki so prejemali aripiprazol, še nadalje povečala, in sicer v povprečju za 2,2 kg, v primerjavi z 0,6 kg pri bolnikih, ki so prejemali placebo.
Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. 
V celoti so v teh preskušanjih cerebrovaskularne neželene učinke zabeležili pri 1,3 % bolnikov, zdravljenih z aripiprazolom, in pri 0,6 % bolnikov, ki so dobivali placebo.
Haemodialysis 
Hemodializa
When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected. 
Med sočasno uporabo aripiprazola in šibkih zaviralcev CYP3A4 (npr. diltiazema) ali CYP2D6 (npr. escitaloprama) je mogoče pričakovati zmerno zvišanje koncentracije plazemskega aripiprazola.
Aripiprazole Mylan Pharma 5 mg tablets Aripiprazole Mylan Pharma 10 mg tablets Aripiprazole Mylan Pharma 15 mg tablets Aripiprazole Mylan Pharma 30 mg tablets 
Aripiprazol Mylan Pharma 5 mg tablete Aripiprazol Mylan Pharma 10 mg tablete Aripiprazol Mylan Pharma 15 mg tablete Aripiprazol Mylan Pharma 30 mg tablete aripiprazol
In the pooled trials, the incidence of low serum prolactin levels in females (<3 ng/ml) and males (<2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7%) and 258/298 (86.6%), respectively. 
Podatki združenih preskušanj kažejo, da je bila pri zdravljenju z aripiprazolom pogostnost nizkih vrednosti prolaktina v serumu pri deklicah (< 3 ng/ml) 58,7 % (27/46), pri dečkih (< 2 ng/ml) pa 86,6 % (258/298).
In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. 
Incidenca podaljšanja intervala QT je bila v kliničnih preskušanjih aripiprazola primerljiva s placebom.
LIST OF EXCIPIENTS Contains maltose. 
Vsebuje maltozo.
Aripiprazole Mylan Pharma contains maltose 
Zdravilo Aripiprazol Mylan Pharma vsebuje maltozo
The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). 
V nekaterih primerih so o njegovem pojavu poročali zgodaj po uvedbi ali zamenjavi antipsihotičnega zdravljenja, tudi pri zdravljenju z aripiprazolom (glejte poglavje 4.8).
In the long term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients. 
V dolgotrajni 26-tedenski vzdrževalni fazi s placebo nadzorovanega preskušanja je bila pojavnost EPS pri bolnikih, ki so se zdravili z aripiprazolom 18,2 %, pri bolnikih, ki so prejemali placebo pa 15,7 %.
In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. 
V kliničnih preskušanjih so poročali o občasnih primerih konvulzij med zdravljenjem z aripiprazolom.
Due to its α1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Aripiprazol deluje antagonistično na adrenergične receptorje α1, zato lahko stopnjuje učinek nekaterih antihipertenzivnih zdravil.
In a long term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. 
V dolgoročnem 26-tedenskem s placebom nadzorovanem preskušanju je bila incidenca EPS pri bolnikih, zdravljenih z aripiprazolom, 19 % in pri bolnikih, ki so dobivali placebo, 13,1 %.
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Aripiprazole Mylan Pharma, you should see your doctor. 
Če opazite kakršen koli neobičajen simptom ob jemanju katerega od teh zdravil skupaj z zdravilom Aripiprazol Mylan Pharma, obiščite zdravnika.
Aripiprazole Mylan Pharma 5 mg tablets Aripiprazole Mylan Pharma 10 mg tablets Aripiprazole Mylan Pharma 15 mg tablets Aripiprazole Mylan Pharma 30 mg tablets aripiprazole 
Aripiprazol Mylan Pharma 5 mg tablete Aripiprazol Mylan Pharma 10 mg tablete Aripiprazol Mylan Pharma 15 mg tablete Aripiprazol Mylan Pharma 30 mg tablete
• The other ingredients for 10, 30 mg are crystalline maltose, microcrystalline cellulose, pregelatinised starch, croscarmellose sodium, iron oxide red (E172) and magnesium stearate. 
Druge sestavine 10, 30 mg zdravila so kristalna maltoza, mikrokristalna celuloza, predgelirani škrob, premreženi natrijev karmelozat, rdeč železov oksid (E172) in magnezijev stearat.
Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12. 
V 12. tednu je bil delež bolnikov s simptomatsko remisijo manije pri uporabi aripiprazola podoben kot pri uporabi litija ali haloperidola.
• The other ingredients for 5 mg are crystalline maltose, microcrystalline cellulose, pregelatinised starch, croscarmellose sodium, indigo carmine (E132) and magnesium stearate. 
Druge sestavine 5 mg zdravila so kristalna maltoza, mikrokristalna celuloza, predgelirani škrob, premreženi natrijev karmelozat, indigotin (E132) in magnezijev stearat.
In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients. 
V drugem dolgoročnem 26tedenskem nadzorovanem preskušanju je bila incidenca EPS pri bolnikih, zdravljenih z aripiprazolom, 14,8 % in pri bolnikih, zdravljenih z olanzapinom, 15,1 %.
In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. 
Klinična preskušanja niso pokazala, da bi aripiprazol povzročil klinično pomembno zvečanje telesne mase.
What Aripiprazole Mylan Pharma look like and contents of the pack Aripiprazole Mylan Pharma 5 mg tablets are blue, round and biconvex of 6.1 mm in diameter, engraved with ‘5' on one side. 
Izgled zdravila Aripiprazol Mylan Pharma in vsebina pakiranja Tablete Aripiprazol Mylan Pharma 5 mg so modre, okrogle in bikonveksne premera 6,1 mm in z vrezano oznako '5' na eni strani.
Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1). 
Zdravilo Aripiprazol Mylan Pharma je indicirano za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I pri mladostnikih, starih 13 let in več.
Common Uncommon 
Neznana pogostnost
• pain killers (such as tramadol and pethidine) used for pain relief 
• zdravila proti bolečinam (kot sta tramadol in petidin) uporabljamo za ublažitev bolečine,
Smoking status 
Kajenje
Falls 
Padci
Be sure to tell your doctor if you take a medicine to keep your blood pressure under control. 
Če jemljete zdravila za uravnavanje krvnega tlaka, morate biti povsem prepričani, da ste o tem obvestili svojega zdravnika.
Weight gain has been reported post-marketing among patients prescribed aripiprazole. 
V obdobju po začetku trženja aripiprazola so pri bolnikih, ki so jim ga predpisali, poročali o povečanju telesne mase.
In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. 
V dveh 3-tedenskih s placebom nadzorovanih preskušanjih samostojnega zdravljenja s fleksibilnim odmerkom pri bolnikih z manično ali mešano epizodo bipolarne motnje I se je po 3 tednih izkazalo, da je aripiprazol pri zmanjšanju maničnih simptomov učinkovitejši od placeba.
When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. 
Pri sočasni uporabi močnih induktorjev CYP3A4 in aripiprazola je treba odmerek aripiprazola zvečati.
Tel: +31 (0)20 426 3300 
Mylan BV Tel: +31 (0)20 426 3300
• The active substance is aripiprazole. 
Zdravilna učinkovina je aripiprazol.
In two long term trials with adolescent (13-17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (< 3 ng/ml) and males (< 2 ng/ml) was 37.0 % and 59.4 %, respectively. 
V dveh dolgotrajnih preskušanjih z mladostniki (13 - 17 let) s shizofrenijo in bipolarno motnjo, ki so se zdravili z aripiprazolom, je bila pogostnost nizke ravni prolaktina v serumu pri ženskah (< 3 ng/ml) 37,0 % in pri moških (< 2 ng/ml) 59,4 %.
Pink, oval and biconvex tablets of 17.1 mm in length, 8.1 mm in width, engraved with “30” on one side 
Roza, ovalne in bikonveksne tablete dolžine 17,1 mm in širine 8,1, mm z vrezano oznako “30” na eni strani.
Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever, sweating, altered mental status, or very rapid or irregular heart beat. 
Če se pojavi togost ali neprožnost mišic z zvišano telesno temperaturo, znojenje, sprememba duševnega stanja ali zelo hiter ali nepravilen srčni utrip, o tem nemudoma obvestite svojega zdravnika.
Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. 
Med sočasno uporabo aripiprazola s karbamazepinom je treba odmerek aripiprazola podvojiti.
The recommended dose for adults is 15 mg once a day. 
Največji odmerek je 30 mg enkrat na dan.
• muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood pressure, abnormal rhythms of the heart. 
akutno zmedenost, krče (epilepsijo), komo, kombinacijo zvišane telesne temperature, hitrega dihanja, znojenja; okorelost mišic in omotičnost ali zaspanost, upočasnjeno dihanje, dušenje, visok ali nizek krvni tlak, motnje srčnega ritma.
When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. 
Prilagajanje odmerka zaradi medsebojnega delovanja Pri sočasni uporabi močnih zaviralcev CYP3A4 ali CYP2D6 in aripiprazola je treba odmerek aripiprazola zmanjšati.
Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered. 
Bolniki s sočasno motnjo pomanjkanja pozornosti (ADHD - Attention deficit hyperactivity disorder) Kljub pogosti sočasni obolevnosti za bipolarno motnjo I in motnjo pomanjkanja pozornosti je na voljo zelo malo podatkov o sočasni uporabi aripiprazola in stimulansov.
Management of overdose 
Ukrepanje v primeru prevelikega odmerka